AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NYXH · NASDAQ · Medical - Specialties

Nyxoah

Commercializes a leadless, battery-free therapy for obstructive sleep apnea.

$1.59

After-hours close−0.01 (−0.90%)

At close$1.61(+2.23%)

Something off on this page? Send us feedback.

Profile

Nyxoah S.A.NYXHHealth Care

Commercializes Genio, a leadless, battery-free hypoglossal-neurostimulation therapy for obstructive sleep apnea. Its single-product business moved from European sales to early U.S. commercialization after FDA approval.

Commercializes Genio, a leadless, battery-free hypoglossal-neurostimulation therapy for obstructive sleep apnea. The system is designed as a single-incision, patient-centered therapy and is the company’s core product, rather than part of a broad device portfolio.

European commercialization followed CE Mark certification, with first German sales preceding the U.S. launch. FDA approval for a subset of adults with moderate-to-severe OSA enabled U.S. commercial activity, while the ordinary shares remain listed in both Brussels and on Nasdaq. The business is therefore shaped by Genio’s regulatory status and the execution of an early U.S. commercialization effort.

Company facts

CEOOlivier Taelman

ListedJul 2, 2021

ExchangeNASDAQ

HeadquartersMont-Saint-Guibert, Belgium

CountryBelgium

Employees184

CIK0001857190

ISINBE0974358906

Key statistics

Market cap$160.1M

EPS (ttm)−$2.51

P/E (ttm)−0.6364

ROE-179.7%

P/B0.9473

P/S6.10

Dividend yield—

Beta2.21vs XLV 0.02

Year to date −64.3% · Average volume (30d) 121.1K

Analysts

Price target, next 12 months$3.50+118.8%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy4 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.60

High$7.00+337.5%

Median$3.50+118.8%

Low$2.31+44.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 6, 2026	Robert W. Baird	Target		$2.85	$2.31
Aug 6, 2026	Oppenheimer	Target		$15	$4
Jul 9, 2026	Robert W. Baird	Target			$2.85
Jun 17, 2026	Stifel Nicolaus	Target		$5	$3
May 13, 2026	Piper Sandler	Reiterate	Overweight	$9	$7

Earnings

EPS

Estimate−$0.38

ReportedDue Nov 5, 2026

Revenue

Estimate$11.6M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.47	−$0.67	−42.6%	$8.6M	$8.8M	+1.5%	−7.09%
May 12, 2026Q1 FY26	−$0.54	−$0.43	+20.4%	$7.0M	$7.4M	+4.4%	+0.33%
Mar 19, 2026Q4 FY25	−$0.65	−$0.68	−4.6%	$5.4M	$6.6M	+23.1%	−0.32%
Nov 13, 2025Q3 FY25	−$0.61	−$0.74	−21.3%	$5.7M	$2.3M	−59.4%	−5.84%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.2M	$1.6M	$2.3M	$6.5M	$8.5M	$8.9M
Gross profit	$762.4K	$984.9K	$1.4M	$4.2M	$2.6M	$5.3M
Operating income	−$23.9M	−$23.0M	−$28.0M	−$21.2M	−$27.5M	−$23.9M
Net income	−$25.9M	−$23.9M	−$27.3M	−$27.2M	−$21.3M	−$38.2M
Diluted EPS	−$0.70	−$0.64	−$0.73	−$0.68	−$0.43	−$0.67
Gross margin	61.8%	63.4%	60.5%	64.2%	30.2%	59.7%
Operating margin	-1,939.8%	-1,481.3%	-1,226.9%	-323.5%	-322.3%	-268.2%

Fiscal years (4-quarter sums)FY21 $988.3K · FY22 $3.6M · FY23 $5.0M · FY24 $5.2M · FY25 $11.6M

Revenue by geography · FY25

Germany$5.2M · 49%

United States$4.2M · 40%

United ARAB Emirates$652.3K · 6%

Switzerland$362.7K · 3%

Netherlands$151.8K · 1%

Italy$32.4K · 0%

Austria$19.7K · 0%

Spain$16.2K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $113.3M · Total debt $60.9M · Total assets $195.2M · Shareholders' equity $96.3M

Dividends

No dividends on record.

Ownership

Institutions 22.10%Insiders —

Shares outstanding 100.07M · Float 58.04M · 58.0% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Aigh Capital Management LLC	14.53M	14.52%	13F	Aug 7, 2026
Orin Hirschman	14.53M	14.50%	13G	Jun 22, 2026
Cochlear Limited	5.85M	5.91%	13D	Jun 11, 2026
CVI Investments, Inc.	4.68M	9.90%	13G	Dec 29, 2025
BNP Paribas Asset Management Holding S.A.	962.5K	0.96%	13F	Aug 13, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.